Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers
Journal of Medicinal Chemistry · 14.12.2023 · 66 (23) · 15629-15647
DOI: 10.1021/acs.jmedchem.3c01233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.11.2023. Verfasst von David B Freeman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Kronos Bio, Inc., 301 Binney Street, 2nd Floor East, Cambridge, Massachusetts 02142, United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kronos Bio.
Abstract (Originalsprache)
Transcriptional deregulation is a hallmark of many cancers and is exemplified by genomic amplifications of the MYC family of oncogenes, which occur in at least 20% of all solid tumors in adults. Targeting of transcriptional cofactors and the transcriptional cyclin-dependent kinase (CDK9) has emerged as a therapeutic strategy to interdict deregulated transcriptional activity including oncogenic MYC. Here, we report the structural optimization of a small molecule microarray hit, prioritizing maintenance of CDK9 selectivity while improving on-target potency and overall physicochemical and pharmacokinetic (PK) properties. This led to the discovery of the potent, selective, orally bioavailable CDK9 inhibitor 28 (KB-0742). Compound 28 exhibits in vivo antitumor activity in mouse xenograft models and a projected human PK profile anticipated to enable efficacious oral dosing. Notably, 28 is currently being investigated in a phase 1/2 dose escalation and expansion clinical trial in patients with relapsed or refractory solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kronos Bio, Inc., 301 Binney Street, 2nd Floor East, Cambridge, Massachusetts 02142, United States.
- Kronos Bio, Inc., 1300 So. El Camino Real Suite 400, San Mateo, California 94402, United States.
- Naylor Olsen Consulting, LLC, 3369 Saddle Wood Court, Lansdale, Pennsylvania 19446, United States.
- TCG Lifesciences Private Limited, Block BN, Plot 7, Salt-lake Electronics Complex, Sector V, Kolkata 700091, West Bengal, India.
- WuXi AppTec (Tianjin) Co., Ltd., 168 NanHai Road, 10th Avenue, TEDA, Tianjin 300457, P. R. China.
- Certara Strategic Consulting, 100 Overlook Center, Suite 101, Princeton, New Jersey 08540, United States.
ORCID-Profile: David B Freeman
Förderung
- Kronos Bio
Zitieren
APA
Freeman, D. B., Hopkins, T. D., Mikochik, P. J., Vacca, J. P., Gao, H., Naylor-Olsen, A., Rudra, S., Li, H., Pop, M. S., Villagomez, R. A., Lee, C., Li, H., Zhou, M., Saffran, D. C., Rioux, N., Hood, T. R., Day, M. A. L., McKeown, M. R., Lin, C. Y., …, & Trotter, B. W. (2023). Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers. Journal of Medicinal Chemistry, 66(23), 15629-15647. https://doi.org/10.1021/acs.jmedchem.3c01233
Vancouver
Freeman DB, Hopkins TD, Mikochik PJ, Vacca JP, Gao H, Naylor-Olsen A, et al. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers. Journal of Medicinal Chemistry. 2023;66(23):15629-15647. doi:10.1021/acs.jmedchem.3c01233
BibTeX
@article{Freeman2023,
author = {Freeman, David B and Hopkins, Tamara D and Mikochik, Peter J and Vacca, Joseph P and Gao, Hua and Naylor-Olsen, Adel and Rudra, Sonali and Li, Huixu and Pop, Marius S and Villagomez, Rosa A and Lee, Christina and Li, Heng and Zhou, Minyun and Saffran, Douglas C and Rioux, Nathalie and Hood, Tressa R and Day, Melinda A L and McKeown, Michael R and Lin, Charles Y and Bischofberger, Norbert and Trotter, B Wesley},
title = {Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {23},
pages = {15629--15647},
doi = {10.1021/acs.jmedchem.3c01233}
}
EUVIMED